文献速递先天性心脏病外科

Fontan术后蛋白丢失性肠病:瑞典30年全国队列研究

Protein-losing enteropathy following Fontan completion: A 30-year national cohort study in Sweden.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-11-18

该研究基于瑞典全国Fontan队列,纳入1993年后出生、2021年前完成Fontan的573例患者,其中28例(4.8%)发生蛋白丢失性肠病(PLE)。右心室形态与PLE相关(OR 2.3,95%CI 1.04-5.0),早期发病者常伴肺静脉淤血史。5年总生存率88%,5年无移植生存率79%。

要点

  • Fontan术后PLE发生率4.8%,中位发病时间1.5年。
  • 右心室形态是PLE的危险因素(OR 2.3)。
  • 早期PLE(<2年)常伴肺静脉淤血史,5年生存率88%。

核心结论

  • Fontan术后PLE仍是严重并发症,死亡率显著。
  • 右心室形态的系统心室患者PLE风险更高。
  • Fontan术后早期诊断PLE者常有肺静脉淤血史。

研究设计与样本

  • 瑞典全国Fontan队列研究,纳入1993年1月1日后出生、2021年1月1日前完成Fontan的患者。
  • 共回顾573例患者的手术记录和病历,诊断18岁前发生的PLE。

主要发现

  • 573例中28例(4.8%)发生PLE,中位发病时间1.5年(IQR 0.5-5.5年)。
  • 右心室形态与PLE相关(OR 2.3;95%CI 1.04-5.0)。
  • 8例(26%)接受心脏移植;5年总生存率88%,5年无移植生存率79%。

关键数值与推荐

  • PLE诊断标准未在摘要中报告。
  • 早期PLE定义为Fontan完成后<2年发病。

临床怎么用

  • 对Fontan术后患者应监测PLE,尤其右心室形态者。
  • 早期发病者需评估肺静脉淤血。
  • 导管介入可用于优化血流动力学,淋巴介入可能增多。
  • 难治性PLE可考虑心脏移植。

局限性

  • 回顾性队列研究,可能存在选择偏倚。
  • 样本量较小(28例PLE),统计效能有限。
  • 未报告PLE诊断标准及具体治疗方案细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize patients with protein-losing enteropathy (PLE) diagnosed before age 18 years within a nationwide Swedish Fontan cohort. METHODS: Surgical records and medical charts were reviewed for all patients born after January 1, 1993, who underwent Fontan completion before January 1, 2021. RESULTS: Among 573 reviewed patients, 28 (4.8%) developed PLE. The median time to onset of PLE after Fontan was 1.5 years (interquartile range, 0.5-5.5 years). Right ventricular morphology was associated with PLE (odds ratio, 2.3; 95% confidence interval, 1.04-5.0). Twenty-three patients (82%) received PLE-directed therapies, including pulmonary vasodilators (n = 17; 61%), subcutaneous heparin (n = 14; 50%), and/or long-term corticosteroids (n = 13; 46%). Eleven patients (39%) underwent a total of 18 catheter interventions, including 1 fenestration and 1 lymphatic intervention. Three pacemaker procedures were performed after a PLE diagnosis. Eight patients underwent heart transplant (26%). Patients with an early onset of PLE (<2 years from Fontan completion) frequently had a history of pulmonary venous congestion. Five-year overall survival was 88%, and 5-year transplant-free survival was 79%. CONCLUSIONS: PLE remains a serious complication following Fontan, with notable mortality. Patients with right ventricular morphology of the systemic ventricle had a higher risk of PLE. Previous pulmonary venous congestion was common when PLE was diagnosed early after Fontan. Catheter-based interventions were frequently used to optimize hemodynamics; lymphatic interventions are likely to become more common. In therapy-refractory patients, heart transplantation remains an option.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Dolk M, Schütz I, Herou E, et al. Protein-losing enteropathy following Fontan completion: A 30-year national cohort study in Sweden. J Thorac Cardiovasc Surg. 2025. PMID: 41260410. doi:10.1016/j.jtcvs.2025.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。